Table 1 Clinical characteristics of all participants.
From: TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes
Treatment with sulfonylurea (A1C <7%) | Failure of treatment with sulfonylurea (A1C≥7%) | P-value | |
|---|---|---|---|
N = 92 | N = 97 | ||
Gender (Male/Female) | 45/47 | 47/50 | 0.95* |
Age (yr) | 78.2 ± 9.6 | 78.3 ± 9.0 | 0.98 |
BMI (kg/m2) | 26.8 ± 5.2 | 27.0 ± 4.7 | 0.71 |
Creatinine (mg/dl) | 1.73 ± 1.20 | 1.52 ± 0.55 | 0.13 |
Creatinine clearence (ml/min) | 42.96 ± 22.61 | 42.10 ± 18.77 | 0.79 |
A1C (%) | 6.13 ± 0.51 | 7.65 ± 1.40 | <0.001 |
Age at onset of diabetes (yr) | 68.0 ± 13.4 | 66.0 ± 10.9 | 0.28 |
Diabetes duration (yr) | 10.2 ± 9.5 | 11.9 ± 8.4 | 0.20 |
Co-medication (n all drugs) | 7 ± 3 | 7 ± 3 | 0.29 |
Sulfonylurea daily dose (mg) | 3.68 ± 6.40 | 4.24 ± 6.85 | 0.56 |
Metformin treatment (n patients) | 32 | 40 | 0.36* |